| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.22 | 0.0005 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.18 | 0.0006 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0007 |
| mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | -0.13 | 0.001 |
| mRNA | JNK-9L | GDSC1000 | pan-cancer | AAC | -0.12 | 0.002 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.11 | 0.003 |
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.003 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.004 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.2 | 0.004 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.18 | 0.006 |